-
Talk to Us: info@nidccglobal.org
-
Location: Washington, DC | Abuja, Nigeria
Language:
Everyday Economic News
AbbVie Loses Colorado 340B Drug Pricing Law Challenge
A Colorado federal judge dismissed AbbVie Inc.'s claims against the state's 340B drug pricing law, ruling that the Colorado law is not federally preempted. This decision aligns with previous rulings in similar cases across the country. The article highlights that Law360 provides comprehensive legal news and analysis on such fast-moving legal issues.
Ra capital funds acquire $7.65m in Artiva Biotherapeutics stock
RA Capital Management and its affiliated funds have acquired approximately $7.65 million worth of Artiva Biotherapeutics (NASDAQ:ARTV) common stock between June 9 and June 11, 2026. These purchases, occurring amidst a period of strong stock momentum for Artiva, increase RA Capital's indirect holdings significantly. Despite the stock appearing overvalued by some metrics, analysts remain bullish, and Artiva has recently received an FDA Regenerative Medicine Advanced Therapy designation for its AlloNK therapy, supporting positive sentiment.
INVESTOR ALERT: Securities Class Action Filed Against ADMA Biologics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP
Kirby McInerney LLP has filed a class action lawsuit against ADMA Biologics, Inc. on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026. The lawsuit alleges that ADMA engaged in an undisclosed related party transaction, used channel stuffing to inflate revenue appearance, and lacked adequate internal controls, leading to significant stock price declines after a short seller report and analyst downgrade. Investors who suffered losses are encouraged to contact the firm by August 10, 2026, to request lead plaintiff appointment.
Failed Obesity Trial And Investor Exit Might Change The Case For Investing In Wave Life Sciences (WVE)
Wave Life Sciences (WVE) recently announced the failure of its obesity candidate WVE-007, coupled with institutional investor Exome Asset Management exiting its entire position. This dual setback is intensifying scrutiny on how Wave Life Sciences will manage its capital and prioritize its remaining RNA-based pipeline. The company's investment narrative now hinges on the success of its AATD and CNS assets, with updated RestorAATion 2 data for WVE-006 identified as a key near-term catalyst.
ADMA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ADMA Biologics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced the filing of a class action lawsuit against ADMA Biologics, Inc. Investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, are encouraged to contact the firm to discuss their legal rights. The lawsuit alleges that ADMA engaged in an undisclosed related-party transaction, used channel stuffing to inflate revenue appearance, and lacked adequate internal controls, which led to a significant stock price drop following a critical report by Culper Research.
Biogen (NASDAQ: BIIB) grants director 1,505 RSUs vesting by 2026
Biogen Inc. director Eric K. Rowinsky was granted 1,505 restricted stock units (RSUs) as part of his compensation, vesting on the earlier of the next annual meeting or June 9, 2026. This award, valued at $0.00 per share, increases his direct holdings to 25,844 shares of Biogen common stock. The grant aims to align his incentives with the company's future performance.
Biogen (NASDAQ: BIIB) director Jesus B. Mantas awarded 1,505-share stock grant
Biogen director Jesus B. Mantas received an equity award of 1,505 shares of Common Stock, increasing his direct ownership to 11,263 shares. This grant was part of his compensation, not a market purchase, and the restricted stock units will vest on the earlier of the company's next annual meeting or June 9, 2026. The transaction is detailed in a Form 4 filing, indicating a neutral impact on the stock.
[Form 4] BIOGEN INC. Insider Trading Activity
This article details a Form 4 SEC filing by BIOGEN INC. (BIIB) reporting insider trading activity. Susan Langer, a director at Biogen, received a grant of 1,505 shares of common stock as a compensation award with a price of $0.00 per share, increasing her direct holdings to 6,634.1 common shares. The restricted stock units from this grant will vest on the earlier of the next annual meeting or the anniversary of the June 9, 2026 grant date.
Amgen’s Repatha Diabetes Data Reframes Cardiometabolic Upside For Investors
Amgen's Repatha, typically known for its cholesterol-lowering capabilities, has shown new promise in reducing major cardiovascular events in high-risk diabetic patients, according to recent VESALIUS-CV Phase 3 data presented at ADA 86th Scientific Sessions. This development re-calibrates Amgen's cardiometabolic market potential, extending beyond its traditional oncology focus. Investors are now watching how these findings will translate into guideline changes, payer coverage, and ultimately, Repatha's market contribution within Amgen's broader portfolio.
12 Health Care Stocks Moving In Thursday's After-Market Session
This article lists several healthcare stocks that experienced significant movement during Thursday's after-market trading session. It highlights both gainers, such as Rocket One and Stablecoin Development, and losers, including Gelteq and VolitionRX, providing their percentage changes and market capitalizations. The information presented is generated by Benzinga's automated content engine and reviewed by an editor.